Cooley advised Inventiva on its $107.7 million initial public offering of 7,478,261 American Depositary Shares or ADSs. Inventiva, whose securities now trade on the Nasdaq Global Market and Euronext Paris under the symbol “IVA,” is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Partners Div Gupta, Rich Segal, and Alison Haggerty led the Cooley team.